共 50 条
- [21] Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisNATURE MEDICINE, 2020, 26 (08) : 1280 - +Brastianos, Priscilla K.Lee, Eudocia QuantCohen, Justine V.Tolaney, Sara M.Lin, Nancy U.Wang, NancyChukwueke, UgonmaWhite, Michael D.Nayyar, NaemaKim, AlbertAlvarez-Breckenridge, ChristopherKrop, IanMahar, Maura KeeleyBertalan, Mia S.Shaw, BrianMora, Joana L.Goss, NathanielSubramanian, MeghaNayak, LakshmiDietrich, JorgForst, Deborah A.Nahed, Brian V.Batchelor, Tracy T.Shih, Helen A.Gerstner, Elizabeth R.Moy, BeverlyLawrence, DonaldGiobbie-Hurder, AnitaCarter, Scott L.Oh, KevinCahill, Daniel P.Sullivan, Ryan J.
- [22] Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trialFRONTIERS IN PHARMACOLOGY, 2022, 13Tian, ZhichaoDong, ShupingZuo, WenliLi, PoZhang, FanGao, ShileiYang, YonghaoLi, ChaoZhang, PengWang, XinWang, JiaqiangYao, Weitao
- [23] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialLANCET ONCOLOGY, 2019, 20 (05): : 711 - 718Makker, VickyRasco, DrewVogelzang, Nicholas J.Brose, Marcia S.Cohn, Allen L.Mier, JamesDi Simone, ChristopherHyman, David M.Stepan, Daniel E.Dutcus, Corina E.Schmidt, Emmett V.Guo, MatthewSachdev, PallaviShumaker, RobertAghajanian, CarolTaylor, Matthew
- [24] Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Zuo, JinWu, LingyingLi, XiaofanFeng, MeiLi, GuilingYin, RutieLi, XiuminKang, ShanSun, HongmeiWei, ShuqingZhang, YunyanWang, YiliLiu, HuWang, WeiSun, LiZhu, ZhituLin, DarenJiang, KuiXiang, SilongNiu, Miao
- [25] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384Xu, XiaotingHuan, JianMiao, HuiWang, HaoWang, YueZhu, HongyuJiang, JunZhou, Juying
- [26] Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trialEUROPEAN JOURNAL OF CANCER, 2023, 182 : 57 - 65Wang, XuanWu, XiaowenYang, YueXu, WeiranTian, HuiLian, BinChi, ZhihongSi, LuSheng, XinanKong, YanZhou, LiMao, LiliLi, SimingTang, BixiaYan, XieqiaoBai, XueGuo, JunCui, ChuanLiang
- [27] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialLANCET ONCOLOGY, 2012, 13 (09): : 879 - 886Di Giacomo, Anna MariaAscierto, Paolo A.Pilla, LorenzoSantinami, MarioFerrucci, Pier FrancescoGiannarelli, DianaMarasco, AntonellaRivoltini, LiciaSimeone, EsterNicoletti, Stefania V. L.Fonsatti, EsterAnnesi, DiegoQueirolo, PaolaTestori, AlessandroRidolfi, RuggeroParmiani, GiorgioMaio, Michele
- [28] Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II TrialJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34)Lan, ChunyanShen, JingxianWang, YinLi, JundongLiu, ZhiminHe, MianCao, XinpingLing, JiayuHuang, JiamingZheng, MinZou, GuorongYan, HaowenLiu, QingYang, FanWei, WeiDeng, YanhongXiong, YingHuang, Xin
- [29] Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trialLANCET ONCOLOGY, 2022, 23 (12): : 1547 - 1557Guadagnolo, B. AshleighBassett, Roland L.Mitra, DevaratiFarooqi, AhsanHempel, CarolineDorber, CourtneyWillis, TiaraWang, Wei-LienRatan, RavinSomaiah, NeetaBenjamin, Robert S.Torres, Keila E.Hunt, Kelly K.Scally, Christopher P.Keung, Emily Z.Satcher, Robert L.Bird, Justin E.Lin, Patrick P.Moon, Bryan S.Lewis, Valerae O.Roland, Christina L.Bishop, Andrew J.
- [30] An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate CancerAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04): : 338 - 341Pezaro, CarmelRosenthal, Mark A.Gurney, HowardDavis, Ian D.Underhill, CraigBoyer, Michael J.Kotasek, DusanSolomon, BenjaminToner, Guy C.